Your session is about to expire
← Back to Search
Other
300 mg QD for Alzheimer's Disease (COG0107 Trial)
Phase 1
Waitlist Available
Research Sponsored by Cognition Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 13 and 15.
Awards & highlights
Summary
This trial tests a drug called CT1812 in 36 older healthy volunteers. Researchers want to see how the drug behaves in their bodies, including how it is absorbed and broken down. Participants will stay at a research unit for a short period to receive the drug and undergo various tests. CT1812 is a new treatment being tested for its safety in healthy volunteers.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 13 and 15.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 13 and 15.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF)- CSF/plasma ratio
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Pharmacokinetics (PK) in plasma
Trial Design
3Treatment groups
Experimental Treatment
Group I: 300 mg QDExperimental Treatment1 Intervention
CT1812 300 mg QD
Group II: 150 mg QDExperimental Treatment1 Intervention
CT1812 150 mg QD
Group III: 150 mg BIDExperimental Treatment1 Intervention
CT1812 150 mg BID
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CT1812
2020
Completed Phase 2
~330
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Cognition TherapeuticsLead Sponsor
11 Previous Clinical Trials
1,244 Total Patients Enrolled
Anthony Caggiano, MDStudy DirectorCognition Therapeutics
4 Previous Clinical Trials
821 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger